Forendo Pharma Ltd

Hormos Medical Corporation

Orion Corporation

Maire Eloranta

Risto A Lammintausta

Pasi Koskimies

Leena Hirvelä

Arja Marketta Kalapudas

Marja Sodervall

Arto J Karjalainen

Lauri V Kangas

Arja Karjalainen

Mikko Unkila

Juha-Matti Savola

Paavo Huhtala

Siegfried Wurster

Marjo Hakola

Victor Cockcroft

Maarit Hillil&auml;

Raimo Saxlund

Marja Södervall

Michael McKenzie

Brian Kearton

Leena HirvelÄ

Arja Kalapudas

The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. 

Prodrugs of 17&#x3b2;-HSD1-inhibitors

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof. 

Prodrugs of 17.BETA.-HSD1-inhibitors

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof. 

Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1

The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2 to R7 are as defined in the claims. The invention further relates to their use as inhibitors of 17&#x3b2;-HSD and in treatment or prevention of steroid hormone de-pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17&#x3b2;-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore-mentioned compounds or pharmaceutically acceptable salts thereof.

Therapeutically active 17-nitrogen substituted estratreinthiazole derivatives as inhibitors of 17&#x3b2;-hydroxysteroid dehydrogenase

The present invention concerns a method for the preparation of therapeutically valuable triphenylbutene derivatives, especially ospemifene or fispemifene.

Method for the preparation of therapeutically valuable triphenylbutene derivatives

The present invention concerns a method for preparation of fispemifene by use of ospemifene as a starting material.

Methods for the preparation of fispemifene from ospemifene

Imidazole derivatives having affinity for &agr;2 receptors

Imidazole derivatives having affinity for alpha2 receptors

Growing community of inventors

Oulu, Finland

Maire Eloranta